NCT00395577View on ClinicalTrials.gov

A Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702

PHASE2CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

November 30, 2006

Study Completion Date

July 31, 2007

Conditions
Rheumatoid Arthritis
Interventions
DRUG

VX-702

Trial Locations (17)

Unknown

Call For Information, Dimitrovgrad

Call For Information, Pleven

Call For Information, Sofia

Call For Information, Veliko Tarnovo

Call For Information, Osijek

Call For Information, Zagreb

Call For Information, Bytom

Call For Information, Krakow

Call for Information, Torun

Call For Information, Żyrardów

Call For Information, Novosibirsk

Call For Information, Saint Petersburg

Call For Information, Saratov

Call For Information, Belgrade

Call For Information, Niska Banja

Call For Information, Zemun

Call For Information, Ljubljana

All Listed Sponsors
lead

Vertex Pharmaceuticals Incorporated

INDUSTRY

NCT00395577 - A Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702 | Biotech Hunter | Biotech Hunter